Values First Advisors Inc. Buys 2,771 Shares of Boston Scientific Co. (NYSE:BSX)

Values First Advisors Inc. raised its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 817.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,110 shares of the medical equipment provider's stock after buying an additional 2,771 shares during the period. Values First Advisors Inc.'s holdings in Boston Scientific were worth $278,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Dunhill Financial LLC boosted its position in shares of Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 152 shares during the last quarter. Global Wealth Strategies & Associates boosted its position in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 250 shares during the last quarter. West Oak Capital LLC bought a new position in shares of Boston Scientific in the 4th quarter worth $29,000. E Fund Management Hong Kong Co. Ltd. bought a new position in shares of Boston Scientific in the 3rd quarter worth $30,000. Finally, Capital Performance Advisors LLP acquired a new stake in Boston Scientific during the 3rd quarter worth $30,000. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the company. Stifel Nicolaus raised their price objective on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. TD Cowen raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, December 12th. Piper Sandler raised their price objective on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Sanford C. Bernstein raised their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, October 24th. Finally, Barclays raised their price objective on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. One investment analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $107.39.

Boston Scientific Stock Performance

Boston Scientific stock traded up $0.06 during midday trading on Friday, reaching $106.20. 3,966,417 shares of the company's stock were exchanged, compared to its average volume of 6,179,673. Boston Scientific Co. has a 52 week low of $65.33 and a 52 week high of $107.17. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The firm has a market cap of $156.51 billion, a price-to-earnings ratio of 84.96, a P/E/G ratio of 2.79 and a beta of 0.80. The stock's 50-day simple moving average is $96.44 and its 200 day simple moving average is $88.29.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. On average, analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 15,087 shares of the company's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the transaction, the chief financial officer now owns 241,451 shares of the company's stock, valued at $25,369,256.57. This trade represents a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 87,326 shares of company stock worth $8,673,948 over the last three months. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.